Abstract
Here we have studied regulatory changes of µ-opioid receptors accompanying in vivo 14-methoxymetopon treatments of rats. Previously, this ligand has been shown to be an extremely potent, centrally acting µ-opioid specific analgesic with low physical dependence, tolerance, respiratory depression, constipation and other side effects. Our work shows that it is a highly potent full agonist of µ-opioid receptor coupled G-protein signaling in vitro, alike the well-known opioid agonist, etorphine. However, unlike etorphine, which desensitized and down-regulated the endogenous µ-opioid receptors, 14-methoxymetopon, given to rats intraperitoneally (i.p.) either acutely or chronically, did not change the binding or G-protein signaling of µ-opioid receptors in rat brain subcellular membranes. Thereby, these data provide further evidence that there is no direct relationship between the efficacy of the ligand in signaling and its ability to internalize or desensitize the receptor. Viewed collectively with published work, it is discussed that µ-opioid receptors display functional selectivity, also called ‘biased agonism’. This concept implies that each ligand may induce unique, ligand-specific receptor conformation that can result in distinct agonist- directed trafficking and/or signal transduction pathways associated with the receptor. Ligand-specific signaling may open up new directions for designing potent analgesics that do not interact with unwanted signaling pathways, which mediate undesired side-effects, such as tolerance and dependence.
Keywords: Opioid, alkaloid, µ-opioid receptor, receptor binding, G-protein signaling, tolerance, dependence, regulation.
Current Pharmaceutical Design
Title:Lack of Regulatory Changes of µ-Opioid Receptors by 14-Methoxymetopon Treatment in Rat Brain. Further Evidence for Functional Selectivity
Volume: 19 Issue: 42
Author(s): Resat Cinar, Orsolya Kekesi, Erika Birkas, Gabriella Fabian, Helmut Schmidhammer and Maria Szucs
Affiliation:
Keywords: Opioid, alkaloid, µ-opioid receptor, receptor binding, G-protein signaling, tolerance, dependence, regulation.
Abstract: Here we have studied regulatory changes of µ-opioid receptors accompanying in vivo 14-methoxymetopon treatments of rats. Previously, this ligand has been shown to be an extremely potent, centrally acting µ-opioid specific analgesic with low physical dependence, tolerance, respiratory depression, constipation and other side effects. Our work shows that it is a highly potent full agonist of µ-opioid receptor coupled G-protein signaling in vitro, alike the well-known opioid agonist, etorphine. However, unlike etorphine, which desensitized and down-regulated the endogenous µ-opioid receptors, 14-methoxymetopon, given to rats intraperitoneally (i.p.) either acutely or chronically, did not change the binding or G-protein signaling of µ-opioid receptors in rat brain subcellular membranes. Thereby, these data provide further evidence that there is no direct relationship between the efficacy of the ligand in signaling and its ability to internalize or desensitize the receptor. Viewed collectively with published work, it is discussed that µ-opioid receptors display functional selectivity, also called ‘biased agonism’. This concept implies that each ligand may induce unique, ligand-specific receptor conformation that can result in distinct agonist- directed trafficking and/or signal transduction pathways associated with the receptor. Ligand-specific signaling may open up new directions for designing potent analgesics that do not interact with unwanted signaling pathways, which mediate undesired side-effects, such as tolerance and dependence.
Export Options
About this article
Cite this article as:
Cinar Resat, Kekesi Orsolya, Birkas Erika, Fabian Gabriella, Schmidhammer Helmut and Szucs Maria, Lack of Regulatory Changes of µ-Opioid Receptors by 14-Methoxymetopon Treatment in Rat Brain. Further Evidence for Functional Selectivity, Current Pharmaceutical Design 2013; 19 (42) . https://dx.doi.org/10.2174/138161281942140105161245
DOI https://dx.doi.org/10.2174/138161281942140105161245 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Physiology of Folic Acid in Health and Disease
Current Drug Metabolism Differential Regulation of microRNAs in Patients with Ischemic Stroke
Current Neurovascular Research Synthetic Curcumin Analogs as Inhibitors of β -Amyloid Peptide Aggregation: Potential Therapeutic and Diagnostic Agents for Alzheimer's Disease
Mini-Reviews in Medicinal Chemistry Halving Your Cake and Eating it, Too: A Case-based Discussion and Review of Metabolic Rehabilitation for Obese Adults with Diabetes
Current Diabetes Reviews Pentapeptides as Minimal Functional Units in Cell Biology and Immunology
Current Protein & Peptide Science The Usefulness of Amyloid Imaging in Predicting the Clinical Outcome After Two Years in Subjects with Mild Cognitive Impairment
Current Alzheimer Research Structure of Cytochrome P450s and Personalized Drug
Current Medicinal Chemistry The General Practitioners Role in Promoting Physical Activity to Older Adults: A Review Based on Program Theory
Current Aging Science Albert Ellis Rational-Emotive Behavior Therapy
Adolescent Psychiatry High Frequency of the Opioid Receptor µ-1 (OPRM1) A118G Polymorphism, an Opioid Drug Therapy Related Gene, in the Indonesian Population
Current Pharmacogenomics and Personalized Medicine Sulforaphane Treatment of Young Men with Autism Spectrum Disorder
CNS & Neurological Disorders - Drug Targets Novel Perspectives in Celiac Disease Therapy
Mini-Reviews in Medicinal Chemistry Correlation of Alzheimer-like Tau Hyperphosphorylation and fMRI Bold Intensity
Current Alzheimer Research A Comparison of Two Statistical Mapping Tools for Automated Brain FDG-PET Analysis in Predicting Conversion to Alzheimer’s Disease in Subjects with Mild Cognitive Impairment
Current Alzheimer Research Opioids in Neuropathic Pain
Current Pharmaceutical Design Metabolic Correction in the Management of Diabetic Peripheral Neuropathy: Improving Clinical Results Beyond Symptom Control
Current Clinical Pharmacology Pro-inflammatory Cytokines Modulate Glial Apolipoprotein E Secretion
Current Alzheimer Research The Role of Amyloid-Beta Derived Diffusible Ligands (ADDLs) in Alzheimers Disease
Current Topics in Medicinal Chemistry Laboratory-Based Studies of Eating Among Children and Adolescents
Current Nutrition & Food Science In Silico Predictions of hERG Channel Blockers in Drug Discovery: From Ligand-Based and Target-Based Approaches to Systems Chemical Biology
Combinatorial Chemistry & High Throughput Screening